Table 2.

Clinicopathological data MS patients and control subjects (immunohistochemistochemical study)

Case	Gender	Age	PMD (h)	DD	MS Type	Demyelination (lesion type)	COD
MS
11	M	43	8:30	17	SP	yes (active)	Pneumonia
12	F	66	6:00	23	SP	yes (active)	Unknown
13	F	60	10:40	7	PP	yes (active)	Euthanasia
14	M	54	8:15	12	PP	yes (active)	Euthanasia
15	F	50	7:35	17	SP	yes (active)	Euthanasia
16	F	62	6:45	25	Unknown	yes (inactive)	Unknown
17	M	63	7:05	28	SP	yes (inactive)	Cardiac arrest after rupture of abdominal aorta
18	M	47	7:15	7	SP	yes (inactive)	Urosepsis with organ failure
19	M	49	8:00	26	PP	yes (inactive)	Pneumonia by MS
20	M	66	7:30	26	PP	yes (inactive)	Ileus
21	M	61	9:15	31	SP	yes (inactive)	Euthanasia
22	F	57	8:40	27	Unknown	yes (inactive)	Respiratory insufficiency by (uro)sepsis
23	F	77	5:43	6	Unknown	no	Respiratory insufficiency with aspiration pneumonia
24	M	71	7:00	26	PP	no	Pneumonia by aspiration
25	F	76	9:45	20	PP	no	Unknown
26	M	50	9:30	24	PP	no	Unknown
27	M	51	11:00	20	Unknown	no	Unknown
28	M	56	9:50	14	PP	no	Cachexia and exhaustion by end stage MS
Control
6	M	84	7:05				Exacerbation of COPD
7	M	56	9:15				Myocardial infarction
8	F	62	7:55				Euthanasia
9	F	92	7:00				Acute death, probably pulmonary embolism
10	F	50	4:10				Metastasized large cell bronchocarcinoma
11	F	62	7:20				Metastases
12	M	82	5:10				Pneumonia/cardiovascular accidents
13	M	78	Unknown				Cardiac arrest after rupture of abdominal aorta
14	F	84	6:55				Myelodysplasia

PMD = Postmortem delay; DD = Disease duration; COD = Cause of death; SP = Secondary progressive; PP = Primary progressive.